A new antituberculosis drug that selectively kills nonmultiplying Mycobacterium tuberculosis.
An important report by Bryk et al. in this issue of Cell Host & Microbe describes the properties of a rhodanine prodrug active against nonmultiplying Mycobacterium tuberculosis (Mtb). Considering the tolerance of nonreplicating Mtb to most currently available agents, such a drug could be a major addition to our antituberculosis arsenal and would greatly benefit control of the disease.
Mitchison
Denis A
DA
Division of Cellular & Molecular Microbiology, St. George's, University of London, Cranmer Terrace, London SW18 0RE, UK. dmitchis@sgul.ac.uk
D000995:Antitubercular Agents / Q000494:pharmacology*; D006801:Humans; D050296:Microbial Viability / Q000187:drug effects*; D009169:Mycobacterium tuberculosis / Q000187:drug effects*; D012236:Rhodanine / Q000494:pharmacology*
D000995:Antitubercular Agents; D012236:Rhodanine